Advertisement


James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer

2015 ASTRO Annual Meeting

Advertisement

James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).



Related Videos

Prostate Cancer

Anthony Zietman, MD, on Accelerating Treatment: RTOG 0415 Study on Prostate Cancer

Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

Symptom Management
Palliative Care
Pain Management

Samuel Chao, MD, on Improving the Consistency of Radiation Oncology Processes

Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).

Gynecologic Cancers

Supriya Chopra, MD, on Reducing Late Bowel Toxicity in Cervical Cancer

Supriya Chopra, MD, of Tata Memorial Hospital, discusses results of the PARCER study, which compared conventional 3D conformal radiotherapy to image-guided intensity-modulated radiotherapy in reducing bowel side effects for women with cervical cancer (Abstract 8).

Gastroesophageal Cancer
Colorectal Cancer

Leonard Gunderson, MD, on the Presidential Symposium Lecture on Upper and Lower GI Cancers

Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse after a complete response to treatment.

Breast Cancer

Reshma Jagsi, MD, DPhil, on the Initial Results of the TBCRC 024 Study on Breast Cancer

Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).

Advertisement

Advertisement




Advertisement